about
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyCombining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?A Retrospective Analysis of Spontaneous Adverse Drug Reactions Reports Relating to Paediatric PatientsOlanzapine in pregnancy and breastfeeding: a review of data from global safety surveillanceEvaluating Social Media Networks in Medicines Safety Surveillance: Two Case StudiesSignal detection and monitoring based on longitudinal healthcare dataHuman milk biomonitoring data: interpretation and risk assessment issues.Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data.Use of logistic regression to combine two causality criteria for signal detection in vaccine spontaneous report data.Drug induced acute pancreatitis: does it exist?Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.Measures to quantify the abuse of prescription opioids: a review of data sources and metrics.Risk management of biosimilars in oncology: each medicine is a work in progress.Predictive modeling of structured electronic health records for adverse drug event detection.A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.Sensitivity of Quantitative Signal Detection in Regards to Pharmacological NeuroenhancementToxicity of infliximab in the course of treatment of Crohn's disease.Methods for identifying suicide or suicidal ideation in EHRs.Detection of pharmacovigilance-related adverse events using electronic health records and automated methods.Effect of consumer reporting on signal detection: using disproportionality analysis.A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.Adverse events associated with paediatric use of complementary and alternative medicine: Results of a Canadian Paediatric Surveillance Program surveyA distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.Psychiatric Symptoms in Patients Receiving Dolutegravir.Review of adverse events associated with false glucose readings measured by GDH-PQQ-based glucose test strips in the presence of interfering sugars.A cohort study of acute pancreatitis in relation to exenatide use.Zolpidem for insomnia.Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Handling Temporality of Clinical Events for Drug Safety Surveillance.Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')2 fragments.Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases.Adverse event reporting with selective serotonin-reuptake inhibitors.
P2860
Q24673716-96D23775-C1AE-486A-B572-DFE8154ED07BQ26996499-148CFD73-ABA2-4131-A497-BE9F65FA94F2Q28552565-EDED8AB1-BA0C-4D89-82A4-9254168F3C86Q30658402-DBA68BFC-90BD-43E7-B94B-AF40311D3085Q30665207-A1D78972-4AD0-4876-87E1-5F6752CD3103Q30706851-EB2371CD-EF5A-482C-B8BF-99EF232BE269Q31006357-F9AD5A85-7D52-47DF-9109-6439DF1D2D5BQ33163984-69A83B6F-2786-45A7-BA73-192A8375EBADQ33723762-941645BE-A05F-445A-ABD9-D720C931890DQ34065405-6CF9F180-49B5-4E1A-8F14-271C050394ADQ34306109-3A17209C-0790-4CFD-B64E-4A1CA44408B8Q34567443-9DCB56F3-8146-42B2-AEAF-537244652D6DQ34589705-A5EF4733-2382-4164-8F1B-70CEDCAD83F4Q34644792-D26B2F2D-5C32-4C95-B298-4E245243D5A8Q35278475-D85223CA-7787-4ADA-8B04-A5D12310E970Q35795287-C663082A-4A0A-47A0-A290-15DA0C4E5DF9Q35852286-7D57D58B-F176-4517-B177-837DE07BC30BQ35902290-C435EBC3-3E8E-4196-A3AF-E9773F80A835Q35972250-3B5A95CE-4154-4FFC-9CD9-916394F3F0CDQ36244289-AFA655FE-73E9-40BF-9F67-C902A19377C7Q36349717-FAA8DCB2-7821-44A8-988E-5FDEBA329DE3Q36519186-A290F9DB-8304-4D4D-BD0F-6878BAE38A89Q36936563-FB5319C1-DE03-45FC-A386-AA873D0F8491Q36984253-22A03EE4-A3D7-4B0F-BB8C-9CB07E582598Q37130608-3DD41577-1915-41E3-AFEC-3768603CED26Q37326985-1BC8F388-A6F2-4F2E-9B1F-6CB28030F0ECQ37574392-FFA3EF99-2EAF-40AB-B167-A4D3851CBD60Q37606315-A508AD07-57A7-4FFC-AD31-48BA27100E02Q37659135-20FFCE91-DA49-45DB-9EF6-11F4AE83657EQ37721053-14AA1D99-F69B-497C-A0C9-8D04FB398D56Q37841739-56ED06B7-FBBF-4D52-A0AE-2C5056994D9BQ37994346-98E4469A-BBD2-46E5-979F-695D085D439DQ38078815-804E092B-EF27-4E28-A189-7735B52F2238Q38423805-D7466A25-3356-446D-86F5-171788374B92Q38501976-216A3412-E149-4B98-9C00-80F645559D61Q38614242-B565D206-9B49-4BC4-A7CF-20D89E7B31F3Q38620987-B398CDCC-D393-4AC2-AEFC-C6DF2967393EQ38997495-01F1B8F5-596B-4D48-ACD6-0BC1C06D0DDCQ40402176-A9B9410C-6209-424E-81C6-183B4FDC304BQ40559019-DADA2663-7A9E-4BAE-90BC-98B89A770ACF
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Limitations and strengths of spontaneous reports data.
@ast
Limitations and strengths of spontaneous reports data.
@en
type
label
Limitations and strengths of spontaneous reports data.
@ast
Limitations and strengths of spontaneous reports data.
@en
prefLabel
Limitations and strengths of spontaneous reports data.
@ast
Limitations and strengths of spontaneous reports data.
@en
P1476
Limitations and strengths of spontaneous reports data.
@en
P2093
Goldman SA
P356
10.1016/S0149-2918(98)80007-6
P478
20 Suppl C
P577
1998-01-01T00:00:00Z